Compare Illumina, Inc. (ILMN) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nano Dimension Ltd - ADR — how do they compare? Illumina, Inc. trades at $190.45 (market cap $27.94B), while Nano Dimension Ltd - ADR trades at $1.54 (market cap $322.08M). The key difference: Illumina, Inc. is far larger — about 86.7× Nano Dimension Ltd - ADR's market cap, and Illumina, Inc. is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ILMN | NNDM | |
|---|---|---|
Market Cap | $27.94B | $322.08M |
Sector | Health | Technology |
52-Week High | $194.33 | $2.14 |
52-Week Low | $91.00 | $1.21 |
Enterprise Value | $29.33B | -$87.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
NNDM trades at $1.545, down 0.32% today, with a bearish technical signal from moving averages. The company reported 2025 revenue of $102.44M but a net loss of $293.30M, reflecting a -286.72% net margin. Cash flow remains negative at -$112.07M, though the balance sheet shows $757.96M in cash against minimal debt. Recent news highlights cost-saving initiatives and a proposed merger with Infinite Epigenetics amid shareholder disputes with Murchinson.
Outlook remains challenged by persistent losses and cash burn, but the strong cash position provides a buffer. The proposed merger introduces strategic uncertainty. Key risks include execution on profitability and shareholder alignment. Analyst sentiment is cautious given the fundamental weaknesses and ongoing corporate actions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
